Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.

Aged CD8-Positive T-Lymphocytes / immunology Carcinoma, Renal Cell / genetics Case-Control Studies Gene Expression Regulation, Neoplastic / immunology Genomics / methods Humans Kidney Neoplasms / genetics Lymphocytes, Tumor-Infiltrating / immunology Male Single-Cell Analysis / methods Transcriptome Tumor Microenvironment / genetics

Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
27 01 2021
Historique:
received: 04 12 2019
accepted: 17 12 2020
entrez: 28 1 2021
pubmed: 29 1 2021
medline: 20 8 2021
Statut: epublish

Résumé

Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to immunotherapies, despite low tumor mutational burden. To characterize the tumor immune microenvironment of ccRCC, we applied single-cell-RNA sequencing (SCRS) along with T-cell-receptor (TCR) sequencing to map the transcriptomic heterogeneity of 25,688 individual CD45

Identifiants

DOI: 10.1038/s42003-020-01625-6 PMID: 33504936 PMC: PMC7840906
pubmed: 33504936
doi: 10.1038/s42003-020-01625-6
pii: 10.1038/s42003-020-01625-6
pmc: PMC7840906
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

122

Subventions

Organisme : NIEHS NIH HHS
ID : P30 ES005605
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA226391
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA260239
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA206255
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA200673
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007337
Pays : United States
Organisme : NIH HHS
ID : S10 OD016199
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA203834
Pays : United States

Références

Saad, A. M. et al. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-Based Study. Clin. Genitourin. Cancer 17, 46–75 (2019).
pubmed: 30391138 doi: 10.1016/j.clgc.2018.10.002
Koneru, R. & Hotte, S. J. Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. Curr. Oncol. 16, S40 (2009).
pubmed: 19478896 pmcid: 2687800 doi: 10.3747/co.v16i0.417
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
pubmed: 30779531 pmcid: 6716603 doi: 10.1056/NEJMoa1816047
Dudani, S. et al. First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J. Clin. Oncol. 37, 584–584 (2019).
doi: 10.1200/JCO.2019.37.7_suppl.584
Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205–214 (2015).
pubmed: 25860605 pmcid: 5905674 doi: 10.1016/j.cell.2015.03.030
Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015).
pubmed: 25688160 doi: 10.1158/1078-0432.CCR-14-2926
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505 pmcid: 4246418 doi: 10.1038/nature13954
Galon, J. et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J. Transl. Med. 4, 273 (2016).
doi: 10.1186/s12967-016-1029-z
Ziai, J. et al. CD8+ T cell infiltration in breast and colon cancer: a histologic and statistical analysis. PLoS ONE 13, e0190158 (2018).
pubmed: 29320521 pmcid: 5761898 doi: 10.1371/journal.pone.0190158
Shimizu, S. et al. Tumor-infiltrating CD8+ T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 8, 80–93 (2019).
pubmed: 30600646 pmcid: 6346233 doi: 10.1002/cam4.1889
Borcherding, N. et al. Keeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer. J. Mol. Biol. 430, 2014–2029 (2018).
pubmed: 29800567 pmcid: 6071324 doi: 10.1016/j.jmb.2018.05.030
Patel, H. D. et al. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncol. 15, 1683–1695 (2019).
pubmed: 30968729 pmcid: 6595543 doi: 10.2217/fon-2018-0951
Nakano, O. et al. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132–5136 (2001).
pubmed: 11431351
Baine, M. K. et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 6, 24990 (2015).
pubmed: 26317902 pmcid: 4694809 doi: 10.18632/oncotarget.4572
Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909–918 (2020).
pubmed: 32472114 doi: 10.1038/s41591-020-0839-y pmcid: 7499153
Choueiri, T. K. et al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J. Clin. Oncol. 37, 101 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.101
Choueiri, T. K. et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 19, 451–460 (2018).
pubmed: 29530667 doi: 10.1016/S1470-2045(18)30107-4
Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749 (2017).
pubmed: 28475899 pmcid: 5422211 doi: 10.1016/j.cell.2017.04.016
Creighton, C. J. et al. Comprehensivemolecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
doi: 10.1038/nature12222
Van Den Heuvel, C. N. A. M. et al. Molecular profiling of druggable targets in clear cell renal cell carcinoma through targeted RNA sequencing. Front. Oncol. 9, 117 (2019).
pubmed: 30881919 pmcid: 6407434 doi: 10.3389/fonc.2019.00117
Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018).
pubmed: 29942092 doi: 10.1038/s41591-018-0078-7
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 (2018).
pubmed: 30388456 pmcid: 6641984 doi: 10.1016/j.cell.2018.10.038
Geissler, K. et al. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology 4, e985082 (2015).
pubmed: 25949868 pmcid: 4368143 doi: 10.4161/2162402X.2014.985082
Chung, W. et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun. 8, 1–12 (2017).
doi: 10.1038/ncomms15081
Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308 (2018).
pubmed: 29961579 pmcid: 6348010 doi: 10.1016/j.cell.2018.05.060
Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018).
pubmed: 29942094 doi: 10.1038/s41591-018-0045-3
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 352, 189–196 (2016).
pubmed: 27124452 pmcid: 4944528 doi: 10.1126/science.aad0501
Beausang, J. F. et al. T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. Proc. Natl Acad. Sci. U. S. A. 114, e10409–e10417 (2017).
pubmed: 29138313 pmcid: 5715779 doi: 10.1073/pnas.1713863114
Zheng, C. et al. Landscape of Infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356 (2017).
pubmed: 28622514 doi: 10.1016/j.cell.2017.05.035
Young, M. D. et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 361, 594–599 (2018).
pubmed: 30093597 pmcid: 6104812 doi: 10.1126/science.aat1699
Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
doi: 10.1038/nature11247
Borcherding, N. & Bormann, N. L. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Research 9, 47 (2020).
pubmed: 32789006 pmcid: 7400693 doi: 10.12688/f1000research.22139.1
Lähnemann, D. et al. Eleven grand challenges in single-cell data science. Genome Biol. 21, 1–35 (2020).
doi: 10.1186/s13059-020-1926-6
Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274–278 (2020).
pubmed: 32103181 doi: 10.1038/s41586-020-2056-8
Luecken, M. D. & Theis, F. J. Current best practices in single‐cell RNA‐seq analysis: a tutorial. Mol. Syst. Biol. 15, e8746 (2019).
pubmed: 31217225 pmcid: 6582955 doi: 10.15252/msb.20188746
Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genom. 19, 477 (2018).
doi: 10.1186/s12864-018-4772-0
Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).
pubmed: 19847166 pmcid: 2783335 doi: 10.1038/nature08460
Plitas, G. et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45, 1122–1134 (2016).
pubmed: 27851913 pmcid: 5134901 doi: 10.1016/j.immuni.2016.10.032
De Simone, M. et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45, 1135–1147 (2016).
pubmed: 27851914 pmcid: 5119953 doi: 10.1016/j.immuni.2016.10.021
Motzer, R. J. et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
pubmed: 29562145 pmcid: 5972549 doi: 10.1056/NEJMoa1712126
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
pubmed: 26406148 pmcid: 5719487 doi: 10.1056/NEJMoa1510665
Vuong, L., Kotecha, R. R., Voss, M. H. & Hakimi, A. A. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 9, 1349–1357 (2019).
pubmed: 31527133 pmcid: 6774890 doi: 10.1158/2159-8290.CD-19-0499
Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).
pubmed: 29301960 pmcid: 6035749 doi: 10.1126/science.aan5951
Şenbabaoğlu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 71, 1–25 (2016).
Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359, 582–587 (2018).
pubmed: 29217585 doi: 10.1126/science.aao4572
Kim, K. T. et al. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol. 17, 1–17 (2016).
doi: 10.1186/s13059-016-0945-9
Zhou, W. et al. Comprehensive analysis of copy number variations in kidney cancer by single-cell exome sequencing. Front. Genet. 10, 1379 (2020).
pubmed: 32038722 pmcid: 6989475 doi: 10.3389/fgene.2019.01379
Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).
pubmed: 28213366 doi: 10.1158/1078-0432.CCR-16-2848
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
pubmed: 31359002 pmcid: 6689255 doi: 10.1038/s41591-019-0522-3
Qi, Y. et al. Tumor-infiltrating CD39
pubmed: 32306075 doi: 10.1007/s00262-020-02563-2
Komohara, Y. et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 102, 1424–1431 (2011).
pubmed: 21453387 doi: 10.1111/j.1349-7006.2011.01945.x
Baldan, V., Griffiths, R., Hawkins, R. E. & Gilham, D. E. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br. J. Cancer 112, 1510–1518 (2015).
pubmed: 25867267 pmcid: 4453687 doi: 10.1038/bjc.2015.96
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 (2019).
pubmed: 31178118 pmcid: 6687398 doi: 10.1016/j.cell.2019.05.031
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
pubmed: 29608179 pmcid: 6700744 doi: 10.1038/nbt.4096
Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 1–15 (2019).
doi: 10.1186/s13059-019-1874-1
Nestorowa, S. et al. A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. Blood 128, e20–e31 (2016).
pubmed: 27365425 pmcid: 5305050 doi: 10.1182/blood-2016-05-716480
Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
pubmed: 30643263 pmcid: 6340744 doi: 10.1038/s41590-018-0276-y
Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416 (2018).
pubmed: 29625055 pmcid: 6066282 doi: 10.1016/j.cell.2018.02.052
Borcherding, N. Single-cell genomics in clear cell renal carcinoma (Version 1). Zenodo. https://doi.org/10.5281/zenodo.4311825 (2020).

Auteurs

Nicholas Borcherding (N)

Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Medical Science Training Program, University of Iowa, Iowa City, IA, USA.
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.

Ajaykumar Vishwakarma (A)

Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA.
Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0003-0823-2933

Andrew P Voigt (AP)

Medical Science Training Program, University of Iowa, Iowa City, IA, USA.

Andrew Bellizzi (A)

Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Jacob Kaplan (J)

Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
ORCID: 0000-0001-8770-485X

Kenneth Nepple (K)

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Aliasger K Salem (AK)

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
ORCID: 0000-0002-1923-6633

Russell W Jenkins (RW)

Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA. rjenkins@mgh.harvard.edu.
Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. rjenkins@mgh.harvard.edu.
ORCID: 0000-0001-6110-2148

Yousef Zakharia (Y)

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. yousef-zakharia@uiowa.edu.
Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. yousef-zakharia@uiowa.edu.
Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. yousef-zakharia@uiowa.edu.
ORCID: 0000-0001-9480-2626

Weizhou Zhang (W)

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. zhangw@ufl.edu.
Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. zhangw@ufl.edu.
Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA. zhangw@ufl.edu.
ORCID: 0000-0002-8236-0346

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Mapping the immune environment in clear cell...
Recherchemedicale.com › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Mapping the immune environment in clear cell...
Recherchemedicale.com › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › Mapping the immune environment in clear cell...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Mapping the immune environment in clear cell...
Recherchemedicale.com › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Mapping the immune environment in clear cell...
Recherchemedicale.com › Disciplines des sciences naturelles › Disciplines des sciences biologiques › Biologie › Génétique › Génomique › Mapping the immune environment in clear cell...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mapping the immune environment in clear cell...
Recherchemedicale.com › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Mapping the immune environment in clear cell...
Recherchemedicale.com › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › Mapping the immune environment in clear cell...
Recherchemedicale.com › Techniques d'investigation › Techniques cytologiques › Analyse sur cellule unique › Mapping the immune environment in clear cell...
Recherchemedicale.com › Phénomènes génétiques › Structures génétiques › Transcriptome › Mapping the immune environment in clear cell...
Recherchemedicale.com › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Mapping the immune environment in clear cell...